Time-programmed activation of CD47 disruption and immunogenic cell death with Cas9 ribonucleoprotein nanocapsule for improved cancer immunotherapy
Yumeng Xing,Jianhui Yang,Chun Wang,Ziyao Kang,Zheng Pan,Jihui Tang,Fenghe Li,Xiao Wang,Xiao-ming Meng,Zhifei Cheng,Yang Liu,Qi Liu
DOI: https://doi.org/10.1016/j.cej.2023.145796
IF: 15.1
2023-09-06
Chemical Engineering Journal
Abstract:Cancer immunotherapy refers to activating the body's antitumor immunity to fight cancer cells, showing great potential in long-term inhibition of tumor growth and recurrence. However, adequate activation of antitumor immunity remains challenging due to overactivated immune checkpoints and poor tumor immunogenicity. To address these challenges, herein, a Cas9 ribonucleoprotein (RNP) nanocapsule (Cas9NC) is described to synergistically activate antitumor immunity by time-programmed activation of CD47 disruption and immunogenic cell death (ICD) of tumor cells. Such Cas9NC is formed by coating RNP with a thin polymer shell made of multiple functional monomers, which not only endows Cas9NC with the capability to deliver payloads into tumor tissues, but also activates CRISPR-Cas9 system and ICD in a time-programmed manner. This time-programmed activation strategy significantly promotes the synergy of two payloads with different onset times. Additionally, CD47 disruption achieve superior therapeutic effects than antibody that achieve temporary conformational blockade. As a result, Cas9NC initiates robust and durable antitumor immune responses, and remarkably inhibits the growth of both primary and abscopal tumors, prevents the malignant tumor recurrence and metastasis. Collectively, this time-programmed activation strategy for synergistic CD47 disruption and ICD provides a promising approach for improved cancer immunotherapy.
engineering, chemical, environmental